Synthetic and Natural Products as Iron Chelators

被引:0
|
作者
Sharpe, Philip C.
Richardson, Des R.
Kalinowski, Danuta S.
Bernhardt, Paul V. [1 ]
机构
[1] Univ Queensland, Sch Chem & Mol Biosci, Ctr Met Biol, Brisbane, Qld 4072, Australia
关键词
beta-thalassemia; deferasirox; deferiprone; deferitrin; desferrioxamine; hemochromatosis; iron; iron overload; PYRIDOXAL ISONICOTINOYL HYDRAZONE; TRANSFERRIN-BOUND-IRON; COORDINATION CHEMISTRY; CRYSTAL-STRUCTURE; GREEN TEA; COMPLEX-FORMATION; FORMATION-CONSTANTS; MOLECULAR-STRUCTURE; OVERLOAD DISEASE; METAL-COMPLEXES;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
An evaluation of existing and proposed Fe chelators, both synthetic and natural products, for the treatment of Fe-overload disease must address a number of issues. There are fundamental parameters that determine the efficacy of a drug: absorption, distribution, metabolism, clearance and toxicity. However, the administration of chelators for Fe overload aims to generate Fe complexes in vivo that are able to be excreted. Hence, the chemical and pharmacological properties of the complexes formed are as equally important as the chelators themselves. The redox properties of the Fe complexes formed are particularly relevant to their toxicity. If both Fe-II and Fe-III oxidation states of the complexes are biologically accessible, then there is potential for the catalytic production of deleterious free radicals by Fenton-type chemistry. In addition, since the burden of Fe overload disease falls predominantly on some of the poorest economies, the cost of a drug must be considered, as well as the mode of delivery. There are also possible issues with the use of naturally occurring ligands, which may form Fe complexes capable of being utilised by opportunistic bacteria. This review will concentrate on recent developments in our chemical understanding of existing chelators approved or proposed for use and will also consider some of the candidates from natural sources that have been recently proposed.
引用
收藏
页码:591 / 607
页数:17
相关论文
共 50 条
  • [41] Oral Iron Chelators
    Kwiatkowski, Janet L.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 24 (01) : 229 - +
  • [42] Hydroxyquinolines as iron chelators
    Pierre, JL
    Baret, P
    Serratrice, G
    CURRENT MEDICINAL CHEMISTRY, 2003, 10 (12) : 1077 - 1084
  • [43] Iron chelators for thalassaemia
    Hershko, C
    Konijn, AM
    Link, G
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 (03) : 399 - 406
  • [44] IRON CHELATORS IN MEDICINE
    HERSHKO, C
    MOLECULAR ASPECTS OF MEDICINE, 1992, 13 (02) : 113 - 165
  • [45] Oral iron Chelators
    Kwiatkowski, Janet L.
    PEDIATRIC CLINICS OF NORTH AMERICA, 2008, 55 (02) : 461 - +
  • [46] ORAL IRON CHELATORS
    不详
    LANCET, 1989, 2 (8670): : 1016 - 1017
  • [47] Oral Iron Chelators
    Cappellini, Maria Domenica
    Pattoneri, Paolo
    ANNUAL REVIEW OF MEDICINE, 2009, 60 : 25 - 38
  • [48] Iron Chelators in Treatment of Iron Overload
    Entezari, Sarina
    Haghi, Seyedeh Mona
    Norouzkhani, Narges
    Sahebnazar, Barsa
    Vosoughian, Fatemeh
    Akbarzadeh, Diba
    Islampanah, Muhammad
    Naghsh, Navid
    Abbasalizadeh, Mohammad
    Deravi, Niloofar
    JOURNAL OF TOXICOLOGY, 2022, 2022
  • [49] NATURAL CHELATORS IN BREWING
    JACOBSEN, T
    LIE, S
    JOURNAL OF THE INSTITUTE OF BREWING, 1975, 81 (01) : 10 - 11
  • [50] The role of iron and iron chelators in zygomycosis
    Symeonidis, A. S.
    CLINICAL MICROBIOLOGY AND INFECTION, 2009, 15 : 26 - 32